http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2615445-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2289971d14c8a733c4987ab6a1325c8d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate | 2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_876337ff896795ef4a2b6cddba9b4200 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca802a1fd92fddb672b99ddc84ee141a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f442a014891995f17e6de64e099de0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512f4ac3de3c711ea43416d470b7280e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27b3d0699df605dfa3d80b99e6e6646e |
| publicationDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2615445-C2 |
| titleOfInvention | Medicinal agent for treating hepatic fibrosis, method for production thereof and method of treating hepatic fibrosis |
| abstract | FIELD: biochemistry. n SUBSTANCE: invention relates to biochemistry, biotechnology and genetic engineering, in particular, to a drug for treating hepatic fibrosis based on a mixture of two non-viral plasmid structures. First non-viral plasmid structure is pC4W-HGFopt and comprises a gene, which codes human hepatocyte growth factor. Second is a pVax1-UPAopt and contains a gene coding human urokinase. In said drug plasmid structures are contained in following concentrations: pC4W-HGFopt – from 0.5 to 0.7 mg/ml; pVax1-UPAopt – from 0.3 to 0.5 mg/ml, wherein total concentration of DNA is 1±0.01 mg/ml. Present invention discloses a method of producing said drug and method of treating hepatic fibrosis using said drug in a pharmaceutically acceptable amount. n EFFECT: present invention enables to produce a drug for treating hepatic fibrosis, having higher efficiency, which is safe and easy to produce. n 12 cl, 28 dwg, 4 tbl, 9 ex |
| priorityDate | 2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 587.